Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E.

Vaccine. 2009 Sep 25;27(42):5913-9. doi: 10.1016/j.vaccine.2009.07.038. Epub 2009 Aug 3.

PMID:
19651171
2.

The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.

Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT).

Pediatr Infect Dis J. 2009 Mar;28(3):220-4. doi: 10.1097/INF.0b013e31819040e7.

PMID:
19209096
3.

Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age.

Gold R, Barreto L, Ferro S, Thippawong J, Guasparini R, Meekison W, Russell M, Mills E, Harrison D, Lavigne P.

Can J Infect Dis Med Microbiol. 2007 Jul;18(4):241-8.

4.

An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus.

Patrick DM, Petric M, Skowronski DM, Guasparini R, Booth TF, Krajden M, McGeer P, Bastien N, Gustafson L, Dubord J, Macdonald D, David ST, Srour LF, Parker R, Andonov A, Isaac-Renton J, Loewen N, McNabb G, McNabb A, Goh SH, Henwick S, Astell C, Guo JP, Drebot M, Tellier R, Plummer F, Brunham RC.

Can J Infect Dis Med Microbiol. 2006 Nov;17(6):330-6.

5.

Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.

Barreto L, Guasparini R, Meekison W, Noya F, Young L, Mills E.

Vaccine. 2007 Nov 23;25(48):8172-9. Epub 2007 Oct 2.

PMID:
17945400
7.

Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age.

Scheifele DW, Halperin SA, Rubin E, Tapiero B, Guasparini R, Meekison W, Predy G, Mills E, Noriega F.

Hum Vaccin. 2005 Sep-Oct;1(5):180-6. Epub 2005 Sep 29.

PMID:
17012882
8.

Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.

Halperin SA, Scheifele D, Mills E, Guasparini R, Humphreys G, Barreto L, Smith B.

Vaccine. 2003 Jun 2;21(19-20):2298-306.

PMID:
12744860
9.

An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.

Halperin SA, Smith B, Russell M, Hasselback P, Guasparini R, Skowronski D, Meekison W, Parker R, Lavigne P, Barreto L.

Vaccine. 2000 Jan 31;18(14):1312-9.

PMID:
10618527
10.

Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.

Halperin SA, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, Meekison W, Eastwood BJ.

Pediatr Infect Dis J. 1999 Sep;18(9):772-9.

PMID:
10493336
11.

Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines.

Scheifele DW, Halperin SA, Guasparini R, Meekison W, Pim C, Barreto L.

J Pediatr. 1999 Aug;135(2 Pt 1):240-5.

PMID:
10431120
12.

A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age.

Scheifele DW, Guasparini R, Lavigne P.

Vaccine. 1999 Feb 12;17(6):543-50.

PMID:
10075160
13.

Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.

Krahn M, Guasparini R, Sherman M, Detsky AS.

Am J Public Health. 1998 Nov;88(11):1638-44.

14.

Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age.

Mills E, Gold R, Thipphawong J, Barreto L, Guasparini R, Meekison W, Cunning L, Russell M, Harrison D, Boyd M, Xie F.

Vaccine. 1998 Apr;16(6):576-85.

PMID:
9569468
15.
16.

Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine.

Halperin SA, Barreto L, Eastwood BJ, Medd L, Guasparini R, Mills E.

Vaccine. 1997 Feb;15(3):295-300.

PMID:
9139489
17.
18.

Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.

Halperin SA, Eastwood B, Barreto L, Mills E, Blatter M, Reisinger K, Bader G, Keyserling H, Roberts EA, Guasparini R, et al.

Scand J Infect Dis. 1995;27(3):279-87.

PMID:
8539554
19.

Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children.

Scheifele DW, Meekison W, Guasparini R, Roberts A, Barreto L, Thipphawong J, Wiltsey S.

Vaccine. 1995 Jan;13(1):104-8.

PMID:
7762265

Supplemental Content

Loading ...
Support Center